SCYNEXIS presents overview of novel cyclophilin inhibitor at Hepatitis C Conference

Drug discovery company, SCYNEXIS, Inc. announced today that management will present an overview on the Company's lead anti-hepatitis C virus (HCV) candidate, SCY-635, at the upcoming Canaccord Adams' Hepatitis C Conference on Thursday, April 1, 2010 at 11:15 am ET at the Peninsula Hotel in New York City.

SCY-635 is a novel cyclophilin inhibitor and represents a new pharmacological class of inhibitors of HCV replication. SCY-635 has shown strong single-agent antiviral activity in a Phase 1b clinical study and has also demonstrated promising antiviral activity when combined with a wide range of mechanistically diverse anti-HCV agents. SCYNEXIS expects to initiate a Phase 2 study for SCY-635 in the second quarter of 2010.

Source: SCYNEXIS